By Professor David Thomas

Journal articles

Collins M; Wilhelm M; Conyers R; Herschtal A; Whelan J; Bielack S; Kager L; Kühne T; Sydes M; Gelderblom H; Ferrari S; Picci P; Smeland S; Eriksson M; Petrilli AS; Bleyer A; Thomas DM, 2013, 'Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: Findings from a meta-analysis', Journal of Clinical Oncology, 31, pp. 2303 - 2312, http://dx.doi.org/10.1200/JCO.2012.43.8598

Lewin J; Khamly K; Mitchell C; Hicks RJ; Toner GC; Ngan S; Powell G; Desai J; Choong P; Stacker S; Slavin J; Thomas DM, 2013, 'Hypoxia, angiogenic markers, and response to neoadjuvant radiotherapy in soft-tissue sarcomas.', Journal of Clinical Oncology, 31, pp. 10567 - 10567, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.10567

Cain JE; McCaw A; Jayasekara WSN; Rossello FJ; Marini KD; Irving AT; Kansara M; Thomas DM; Ashley DM; Watkins DN, 2013, 'Sustained low-dose treatment with the Histone deacetylase inhibitor LBH589 induces terminal differentiation of osteosarcoma cells', Sarcoma, 2013, http://dx.doi.org/10.1155/2013/608964

Harvey KF; Zhang X; Thomas DM, 2013, 'The Hippo pathway and human cancer', Nature Reviews Cancer, 13, pp. 246 - 257, http://dx.doi.org/10.1038/nrc3458

Lewin J; Thomas D, 2013, 'Denosumab: A new treatment option for giant cell tumor of bone', Drugs of Today, 49, pp. 693 - 700, http://dx.doi.org/10.1358/dot.2013.49.11.2064725

Savage SA; Mirabello L; Wang Z; Gastier-Foster JM; Gorlick R; Khanna C; Flanagan AM; Tirabosco R; Andrulis IL; Wunder JS; Gokgoz N; Patiño-Garcia A; Sierrasesúmaga L; Lecanda F; Kurucu N; Ilhan IE; Sari N; Serra M; Hattinger C; Picci P; Spector LG; Barkauskas DA; Marina N; De Toledo SRC; Petrilli AS; Amary MF; Halai D; Thomas DM; Douglass C; Meltzer PS; Jacobs K; Chung CC; Berndt SI; Purdue MP; Caporaso NE; Tucker M; Rothman N; Landi MT; Silverman DT; Kraft P; Hunter DJ; Malats N; Kogevinas M; Wacholder S; Troisi R; Helman L; Fraumeni JF; Yeager M; Hoover RN; Chanock SJ, 2013, 'Genome-wide association study identifies two susceptibility loci for osteosarcoma', Nature Genetics, 45, pp. 799 - 803, http://dx.doi.org/10.1038/ng.2645

Lewin J; Wieringa S; Collins M; Desai J; Orme L; Lingaratnam S; Thomas DM, 2013, 'Intra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: a retrospective review', CLINICAL SARCOMA RESEARCH, 3, http://dx.doi.org/10.1186/2045-3329-3-15

Lewin J; Puri A; Quek R; Ngan R; Alcasabas AP; Wood D; Thomas D, 2013, 'Management of sarcoma in the asia-pacific region: Resource-stratified guidelines', Lancet Oncology, 14, pp. e562 - e570, http://dx.doi.org/10.1016/S1470-2045(13)70475-3

Angoa-Pérez M; Kane MJ; Briggs DI; Francescutti DM; Sykes CE; Shah MM; Thomas DM; Kuhn DM, 2013, 'Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA.', J Neurochem, 125, pp. 102 - 110, http://dx.doi.org/10.1111/jnc.12114

Young M-A; Herlihy A; Mitchell G; Thomas DM; Ballinger M; Tucker K; Lewis CR; Neuhaus S; Halliday J, 2013, 'The attitudes of people with sarcoma and their family towards genomics and incidental information arising from genetic research', Clinical Sarcoma Research, 3, pp. 11 - 11, http://dx.doi.org/10.1186/2045-3329-3-11

Bhoopalan V; Han SG; Shah MM; Thomas DM; Bhalla DK, 2013, 'Tobacco smoke modulates ozone-induced toxicity in rat lungs and central nervous system.', Inhal Toxicol, 25, pp. 21 - 28, http://dx.doi.org/10.3109/08958378.2012.751143

Guagnano V; Kauffmann A; Wöhrle S; Stamm C; Ito M; Barys L; Pornon A; Yao Y; Li F; Zhang Y; Chen Z; Wilson CJ; Bordas V; Le Douget M; Alex Gaither L; Borawski J; Monahan JE; Venkatesan K; Brümmendorf T; Thomas DM; Garcia-Echeverria C; Hofmann F; Sellers WR; Graus-Porta D, 2012, 'FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor', Cancer Discovery, 2, pp. 1118 - 1133, http://dx.doi.org/10.1158/2159-8290.CD-12-0210

Paget C; Duret H; Ngiow SF; Kansara M; Thomas DM; Smyth MJ, 2012, 'Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma', Oncoimmunology, 1, pp. 1313 - 1322, http://dx.doi.org/10.4161/onci.21680

Kelleher FC; Cain JE; Healy JM; Watkins DN; Thomas DM, 2012, 'Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma', Pharmacology and Therapeutics, 136, pp. 153 - 168, http://dx.doi.org/10.1016/j.pharmthera.2012.08.004

Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I, 2012, 'Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone', Clinical Cancer Research, 18, pp. 4415 - 4424, http://dx.doi.org/10.1158/1078-0432.CCR-12-0578

Ray-Coquard I; Thomas D, 2012, 'Targeted therapies: Pazopanib for soft-tissue sarcoma: A PALETTE of data emerges', Nature Reviews Clinical Oncology, 9, pp. 431 - 432, http://dx.doi.org/10.1038/nrclinonc.2012.113

Pedeutour F; Maire G; Pierron A; Thomas DM; Garsed DW; Bianchini L; Duranton-Tanneur V; Cortes-Maurel A; Italiano A; Squire JA; Coindre JM, 2012, 'A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions', Virchows Archiv, 461, pp. 67 - 78, http://dx.doi.org/10.1007/s00428-012-1256-5

Hubbard J; Thomas DM; Yothers G; Green E; Blanke C; O'Connell MJ; Labianca R; Shi Q; Bleyer A; De Gramont A; Sargent D, 2012, 'Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: Findings from the adjuvant colon cancer endpoints data set', Journal of Clinical Oncology, 30, pp. 2334 - 2339, http://dx.doi.org/10.1200/JCO.2011.41.1975

Thomas DM, 2012, 'RANKL, denosumab, and giant cell tumor of bone', Current Opinion in Oncology, 24, pp. 397 - 403, http://dx.doi.org/10.1097/CCO.0b013e328354c129

Angoa-Perez M; Kane MJ; Briggs DI; Sykes CE; Shah MM; Francescutti DM; Rosenberg DR; Thomas DM; Kuhn DM, 2012, 'Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivity', JOURNAL OF NEUROCHEMISTRY, 121, pp. 974 - 984, http://dx.doi.org/10.1111/j.1471-4159.2012.07739.x

Lemech CR; Fontela A; Arkenau H-T; Chin MTM; Li S; Liauw WS; Thomas D; De Souza PL, 2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585

Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; Van Der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY, 2012, 'Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis', Cancer, 118, pp. 1649 - 1655, http://dx.doi.org/10.1002/cncr.26409

Thomas DM; Savage SA; Bond GL, 2012, 'Hereditary and environmental epidemiology of sarcomas', CLINICAL SARCOMA RESEARCH, 2, http://dx.doi.org/10.1186/2045-3329-2-13

Kelleher FC; Thomas DM, 2012, 'Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours', CLINICAL SARCOMA RESEARCH, 2, http://dx.doi.org/10.1186/2045-3329-2-6

Dyson GJ; Thompson K; Palmer S; Thomas DM; Schofield P, 2012, 'The relationship between unmet needs and distress amongst young people with cancer', Supportive Care in Cancer, 20, pp. 75 - 85, http://dx.doi.org/10.1007/s00520-010-1059-7

Blay J; Chawla S; Choy E; Grimer RJ; Ferrari S; Reichardt P; Rutkowski P; Thomas D; Qian Y; Jacobs I, 2012, 'Efficacy and Safety of Denosumab in Giant Cell Tumor of Bone: Updated Results with Independent Radiographic Assessment of Response', Annals of Oncology, 23, pp. ix479 - ix479, http://dx.doi.org/10.1016/s0923-7534(20)34053-9

Thomas DM; Ballinger ML, 2012, 'Inherited and de novo germline TP53 mutations in adult-onset sarcoma', Hereditary cancer in clinical practice, 10, pp. A3 - A3, http://dx.doi.org/10.1186/1897-4287-10-s2-a3

Thomas DM; Ballinger ML, 2012, 'Inherited and de novo germline TP53 mutations in adult-onset sarcoma', Hereditary cancer in clinical practice, 10, pp. A26 - A26, http://dx.doi.org/10.1186/1897-4287-10-s2-a26

Angoa-Pérez M; Kane MJ; Francescutti DM; Sykes KE; Shah MM; Mohammed AM; Thomas DM; Kuhn DM, 2012, 'Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum.', J Neurochem, 120, pp. 1097 - 1107, http://dx.doi.org/10.1111/j.1471-4159.2011.07632.x

Mahendran K; Ballinger M; Kirk J; Thomas D; Tattersall M, 2012, 'Pathogenic germline TP53 mutations in adult sarcoma patients; implications for treatment and screening – description of an upcoming project', Hereditary cancer in clinical practice, 10, pp. A61 - A61, http://dx.doi.org/10.1186/1897-4287-10-s2-a61

Thomas DM; Wilhelm M; Cleton-Jansen A-M; Dirksen U; Entz-Werle N; Gelderblom H; Hassan B; Juergens H; Koster J; Kovar H; Lankester AC; Lewis IJ; Myklebost O; Nathrath MHM; Picci P; Whelan JS; Hogendoorn PCW; Bielack SS, 2011, 'Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology', JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 1, pp. 118 - 123, http://dx.doi.org/10.1089/jayao.2012.0005

Clark JCM; Akiyama T; Thomas DM; Labrinidis A; Evdokiou A; Galloway SJ; Kim HS; Dass CR; Choong PFM, 2011, 'RECK in osteosarcoma: A novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic model', Cancer, 117, pp. 3517 - 3528, http://dx.doi.org/10.1002/cncr.25757

Blanke CD; Bot BM; Thomas DM; Bleyer A; Kohne CH; Seymour MT; De Gramont A; Goldberg RM; Sargent DJ, 2011, 'Impact of young age on treatment efficacy and safety in advanced colorectal cancer: A pooled analysis of patients from nine first-line phase III chemotherapy trials', Journal of Clinical Oncology, 29, pp. 2781 - 2786, http://dx.doi.org/10.1200/JCO.2010.33.5281

Thomas DM, 2011, 'Lessons from the deep study of rare tumours', Journal of Pathology, 224, pp. 306 - 308, http://dx.doi.org/10.1002/path.2928

Blay J; Chawla SP; Martin Broto J; Choy E; Dominkus M; Engellau J; Grimer R; Henshaw RM; Palmerini E; Reichardt P; Rutkowski P; Skubitz KM; Thomas DM; Zhao Y; Qian Y; Jacobs IA, 2011, 'Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study.', Journal of Clinical Oncology, 29, pp. 10034 - 10034, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.10034

Thomas D; Moore A, 2011, 'Counterpoints in cancer: The somatic mutation theory under attack', Bioessays, 33, pp. 313 - 314, http://dx.doi.org/10.1002/bies.201190016

Thomas DM; Conyers R; Young S, 2011, 'Liposarcoma: Molecular genetics and therapeutics', Sarcoma, 2011, http://dx.doi.org/10.1155/2011/483154

Newnham GM; Conron M; McLachlan SA; Dobrovic A; Do H; Li J; Opeskin K; Thompson N; Wright GM; Thomas DM, 2011, 'Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer', BMC Cancer, 11, http://dx.doi.org/10.1186/1471-2407-11-93

Aubin S; Barr R; Rogers P; Schacter B; Bielack SS; Ferrari A; Manchester RA; McMaster K; Morgan S; Patterson M; Petrilli AS; Ribera J-M; Shaw P; Thomas DM; Treadgold C, 2011, 'What Should the Age Range Be for AYA Oncology?', JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 1, pp. 3 - 10, http://dx.doi.org/10.1089/jayao.2011.1505

Ito M; Barys L; O'Reilly T; Young S; Gorbatcheva B; Monahan J; Zumstein-Mecker S; Choong PF; Dickinson I; Crowe P; Hemmings C; Desai J; Thomas DM; Lisztwan J, 2011, 'Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis', Clinical Cancer Research, 17, pp. 416 - 426, http://dx.doi.org/10.1158/1078-0432.CCR-10-2050

Neilsen PM; Pishas KI; Callen DF; Thomas DM, 2011, 'Targeting the p53 pathway in Ewing Sarcoma', Sarcoma, 2011, http://dx.doi.org/10.1155/2011/746939

Lockwood WW; Stack D; Morris T; Grehan D; O'Keane C; Stewart GL; Cumiskey J; Lam WL; Squire JA; Thomas DM; O'Sullivan MJ, 2011, 'Cyclin E1 is amplified and overexpressed in osteosarcoma', Journal of Molecular Diagnostics, 13, pp. 289 - 296, http://dx.doi.org/10.1016/j.jmoldx.2010.11.020

Collins IM; Thomas DM, 2011, 'Novel approaches to treatment of leiomyosarcomas', Current Oncology Reports, 13, pp. 316 - 322, http://dx.doi.org/10.1007/s11912-011-0173-0

Kuhn DM; Angoa-Perez M; Thomas DM, 2011, 'Nucleus Accumbens Invulnerability to Methamphetamine Neurotoxicity', ILAR JOURNAL, 52, pp. 352 - 365, http://dx.doi.org/10.1093/ilar.52.3.352

Hemmings C; Miles C; Slavin J; Bonar SF; Graf N; Austen L; Thomas D; Desai J; Barry P, 2011, 'Optimising the management of soft tissue tumours', Pathology, 43, pp. 295 - 301, http://dx.doi.org/10.1097/PAT.0b013e3283464427

Roudier M; Blay* JY; Chawla S; Manivel C; Nelson SD; Thomas D; Woody L; Soriano R; Jun S; Jacobs I, 2011, 'Denosumab decreases proliferation in giant cell tumor of bone (GCTB)', Bone, 48, pp. S15 - S15, http://dx.doi.org/10.1016/j.bone.2010.10.039

Thomas DM; Albritton KH; Ferrari A, 2010, 'Adolescent and young adult oncology: An emerging field', Journal of Clinical Oncology, 28, pp. 4781 - 4782, http://dx.doi.org/10.1200/JCO.2010.30.5128

Ferrari A; Thomas D; Franklin ARK; Hayes-Lattin BM; Mascarin M; Van Der Graaf W; Albritton KH, 2010, 'Starting an Adolescent and Young Adult Program: Some success stories and some obstacles to overcome', Journal of Clinical Oncology, 28, pp. 4850 - 4857, http://dx.doi.org/10.1200/JCO.2009.23.8097

Thomas DM, 2010, 'Importance of molecular genetics of sarcomas', Cancer Forum, 34, pp. 154 - 156

Thomas D, 2010, 'The hard and soft sides of cancer programming', Bioessays, 32, pp. 837 - 838, http://dx.doi.org/10.1002/bies.201090036

Back to profile page